A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes
The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pum...
Gespeichert in:
Veröffentlicht in: | Endocrine practice 2015-01, Vol.21 (1), p.91-92 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 92 |
---|---|
container_issue | 1 |
container_start_page | 91 |
container_title | Endocrine practice |
container_volume | 21 |
creator | Rayfield, Elliot J |
description | The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pump, which stops insulin delivery for up to 2 hours when the interstitial glucose concentration reaches 70 mg/dL. The Diabetes Control and Complications Trial first showed a clear relationship between diabetic microvascular complications and glycemic control. Others have posited data supporting a relationship between macrovascular disease and glycemic control. In addition to achieving an optimum glycated hemoglobin (HbA1c) level of |
doi_str_mv | 10.4158/EP14443.CO |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652422124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652422124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c274t-4416f3fbbe7969e4ac8f754b6faaede501917a2851d3a78e58fc9d3f53c7ff583</originalsourceid><addsrcrecordid>eNpdkMtKw0AUhgdRbK1ufAAZcCNCauaWmVmWUC9QqAsFcRMmyRlNaS7OTIS-vQmtLlydn8N3fg4fQpcknnMi1N3ymXDO2TxdH6Ep0YxHlMfseMiCxZHS5G2CzrzfxDGNNVGnaEIF1TKRbIreF7gD5zsoQvUNuLXYQ-NbF5n-o4YmQImrxvfbqsFdX3c4fIIz3W5YjhEHByaM3HgZdh1ggsvK5BDAn6MTa7YeLg5zhl7vly_pY7RaPzyli1VUUMlDxDlJLLN5DlInGrgplJWC54k1BkoQMdFEGqoEKZmRCoSyhS6ZFayQ1grFZuhm39u59qsHH7K68gVst6aBtvcZSQTllBLKB_T6H7ppe9cM340Uk3KQxwbqdk8VrvXegc06V9XG7TISZ6Px7GA8S9cDfHWo7PMayj_0VzH7AZdFe4U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1653779343</pqid></control><display><type>article</type><title>A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Rayfield, Elliot J</creator><creatorcontrib>Rayfield, Elliot J</creatorcontrib><description>The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pump, which stops insulin delivery for up to 2 hours when the interstitial glucose concentration reaches 70 mg/dL. The Diabetes Control and Complications Trial first showed a clear relationship between diabetic microvascular complications and glycemic control. Others have posited data supporting a relationship between macrovascular disease and glycemic control. In addition to achieving an optimum glycated hemoglobin (HbA1c) level of <6.5% (AACE), or <7.0% (ADA, EASD), one should not forget the role of glycemic variability. Not only does a minimal degree of glycemic variability improve the patient's quality of life, but increased glycemic variability correlates with the urinary excretion of 8-iso prostaglandin F2α, increased oxidative stress, and a presumed increase in the rate of diabetic complication.</description><identifier>ISSN: 1530-891X</identifier><identifier>EISSN: 1934-2403</identifier><identifier>DOI: 10.4158/EP14443.CO</identifier><identifier>PMID: 25297673</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Blood Glucose ; Diabetes Mellitus, Type 1 - drug therapy ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Infusion Systems ; Insulins</subject><ispartof>Endocrine practice, 2015-01, Vol.21 (1), p.91-92</ispartof><rights>Copyright Allen Press Publishing Services Jan 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c274t-4416f3fbbe7969e4ac8f754b6faaede501917a2851d3a78e58fc9d3f53c7ff583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1653779343?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,4009,27902,27903,27904,64361,64363,64365,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25297673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rayfield, Elliot J</creatorcontrib><title>A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes</title><title>Endocrine practice</title><addtitle>Endocr Pract</addtitle><description>The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pump, which stops insulin delivery for up to 2 hours when the interstitial glucose concentration reaches 70 mg/dL. The Diabetes Control and Complications Trial first showed a clear relationship between diabetic microvascular complications and glycemic control. Others have posited data supporting a relationship between macrovascular disease and glycemic control. In addition to achieving an optimum glycated hemoglobin (HbA1c) level of <6.5% (AACE), or <7.0% (ADA, EASD), one should not forget the role of glycemic variability. Not only does a minimal degree of glycemic variability improve the patient's quality of life, but increased glycemic variability correlates with the urinary excretion of 8-iso prostaglandin F2α, increased oxidative stress, and a presumed increase in the rate of diabetic complication.</description><subject>Blood Glucose</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Glycated Hemoglobin A</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Insulins</subject><issn>1530-891X</issn><issn>1934-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkMtKw0AUhgdRbK1ufAAZcCNCauaWmVmWUC9QqAsFcRMmyRlNaS7OTIS-vQmtLlydn8N3fg4fQpcknnMi1N3ymXDO2TxdH6Ep0YxHlMfseMiCxZHS5G2CzrzfxDGNNVGnaEIF1TKRbIreF7gD5zsoQvUNuLXYQ-NbF5n-o4YmQImrxvfbqsFdX3c4fIIz3W5YjhEHByaM3HgZdh1ggsvK5BDAn6MTa7YeLg5zhl7vly_pY7RaPzyli1VUUMlDxDlJLLN5DlInGrgplJWC54k1BkoQMdFEGqoEKZmRCoSyhS6ZFayQ1grFZuhm39u59qsHH7K68gVst6aBtvcZSQTllBLKB_T6H7ppe9cM340Uk3KQxwbqdk8VrvXegc06V9XG7TISZ6Px7GA8S9cDfHWo7PMayj_0VzH7AZdFe4U</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Rayfield, Elliot J</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes</title><author>Rayfield, Elliot J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c274t-4416f3fbbe7969e4ac8f754b6faaede501917a2851d3a78e58fc9d3f53c7ff583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood Glucose</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Glycated Hemoglobin A</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Insulins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rayfield, Elliot J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rayfield, Elliot J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes</atitle><jtitle>Endocrine practice</jtitle><addtitle>Endocr Pract</addtitle><date>2015-01</date><risdate>2015</risdate><volume>21</volume><issue>1</issue><spage>91</spage><epage>92</epage><pages>91-92</pages><issn>1530-891X</issn><eissn>1934-2403</eissn><abstract>The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pump, which stops insulin delivery for up to 2 hours when the interstitial glucose concentration reaches 70 mg/dL. The Diabetes Control and Complications Trial first showed a clear relationship between diabetic microvascular complications and glycemic control. Others have posited data supporting a relationship between macrovascular disease and glycemic control. In addition to achieving an optimum glycated hemoglobin (HbA1c) level of <6.5% (AACE), or <7.0% (ADA, EASD), one should not forget the role of glycemic variability. Not only does a minimal degree of glycemic variability improve the patient's quality of life, but increased glycemic variability correlates with the urinary excretion of 8-iso prostaglandin F2α, increased oxidative stress, and a presumed increase in the rate of diabetic complication.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>25297673</pmid><doi>10.4158/EP14443.CO</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-891X |
ispartof | Endocrine practice, 2015-01, Vol.21 (1), p.91-92 |
issn | 1530-891X 1934-2403 |
language | eng |
recordid | cdi_proquest_miscellaneous_1652422124 |
source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
subjects | Blood Glucose Diabetes Mellitus, Type 1 - drug therapy Glycated Hemoglobin A Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Insulins |
title | A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A56%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20perspective%20of%20sensor-augmented%20insulin%20pump%20therapy%20in%20the%20treatment%20of%20type%201%20diabetes&rft.jtitle=Endocrine%20practice&rft.au=Rayfield,%20Elliot%20J&rft.date=2015-01&rft.volume=21&rft.issue=1&rft.spage=91&rft.epage=92&rft.pages=91-92&rft.issn=1530-891X&rft.eissn=1934-2403&rft_id=info:doi/10.4158/EP14443.CO&rft_dat=%3Cproquest_cross%3E1652422124%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1653779343&rft_id=info:pmid/25297673&rfr_iscdi=true |